Specific instructions for taking Erdafitinib/Bocco

Erdafitinib (Erdafitinib) is an oral targeted drug that needs to be taken strictly according to the doctor's recommendations during treatment. The method of use of the drug is crucial to the effectiveness of the treatment. Patients with bladder cancer often need to ensure that FGFR gene alterations are present in their tumor specimens before starting treatment. This is critical to determining whether erdafitinib is suitable for use.

1. Starting dose and adjustment: The recommended starting dose of erdafitinib is usually 8 mg once a day, and patients need to start taking it under the guidance of a doctor. It is generally recommended that the dose be gradually increased during the first 14 to 21 days of treatment, up to a maximum dose of 9 mg once daily, based on patient tolerance and treatment response. When increasing the dose, patients need to be closely monitored for potential side effects such as hyperphosphatemia, which is also one of the common problems during the use of erdafitinib. When adjusting the dose, the doctor will decide whether to continue to increase the dose or adjust the treatment plan based on the patient's blood test results and health status.

2. Precautions for taking: Erdafitinib is an oral drug. Patients can take it at the same time every day according to the doctor's advice, preferably after meals to reduce gastrointestinal discomfort. Each time you take the medicine, you must swallow the tablet whole and do not chew or break the tablet. At the same time, patients should avoid adjusting the drug dosage or stopping the drug on their own while taking it, unless under the guidance of a doctor.

During treatment, patients need regular blood tests to monitor kidney function, liver function and phosphate levels to ensure safe use of the drug. If side effects or drug intolerance occur, the doctor may adjust the treatment plan or consider other alternative treatments based on the situation. For some patients, especially those with hepatic and renal insufficiency, the drug dosage may need to be further adjusted based on individual circumstances.

Reference materials：https://www.balversa.com/